173 related articles for article (PubMed ID: 16153821)
1. Ospemifene inhibits the growth of dimethylbenzanthracene-induced mammary tumors in Sencar mice.
Wurz GT; Read KC; Marchisano-Karpman C; Gregg JP; Beckett LA; Yu Q; Degregorio MW
J Steroid Biochem Mol Biol; 2005 Nov; 97(3):230-40. PubMed ID: 16153821
[TBL] [Abstract][Full Text] [Related]
2. Ineffectiveness of American ginseng in the prevention of dimethylbenzanthracene-induced mammary tumors in mice.
Wurz GT; Marchisano-Karpman C; DeGregorio MW
Oncol Res; 2006; 16(6):251-60. PubMed ID: 17476970
[TBL] [Abstract][Full Text] [Related]
3. Vaginal effects of ospemifene in the ovariectomized rat preclinical model of menopause.
Unkila M; Kari S; Yatkin E; Lammintausta R
J Steroid Biochem Mol Biol; 2013 Nov; 138():107-15. PubMed ID: 23665515
[TBL] [Abstract][Full Text] [Related]
4. Tamoxifen, raloxifene and the prevention of breast cancer.
Bentrem DJ; Craig Jordan V
Minerva Endocrinol; 2002 Jun; 27(2):127-39. PubMed ID: 11961504
[TBL] [Abstract][Full Text] [Related]
5. Ospemifene: a first-in-class, non-hormonal selective estrogen receptor modulator approved for the treatment of dyspareunia associated with vulvar and vaginal atrophy.
DeGregorio MW; Zerbe RL; Wurz GT
Steroids; 2014 Nov; 90():82-93. PubMed ID: 25087944
[TBL] [Abstract][Full Text] [Related]
6. Tissue selectivity of ospemifene: pharmacologic profile and clinical implications.
Kangas L; Unkila M
Steroids; 2013 Dec; 78(12-13):1273-80. PubMed ID: 24055829
[TBL] [Abstract][Full Text] [Related]
7. Selective estrogen receptor modulators inhibit growth and progression of premalignant lesions in a mouse model of ductal carcinoma in situ.
Namba R; Young LJ; Maglione JE; McGoldrick ET; Liu S; Wurz GT; DeGregorio MW; Borowsky AD; MacLeod CL; Cardiff RD; Gregg JP
Breast Cancer Res; 2005; 7(6):R881-9. PubMed ID: 16280035
[TBL] [Abstract][Full Text] [Related]
8. Effects of ospemifene on breast tissue morphology and proliferation: a comparative study versus other selective estrogen receptor modulators in ovariectomized rats.
Kangas L; Härkönen P; Väänänen K; Keskitalo J; Eigéliené N
Horm Metab Res; 2014 May; 46(5):328-32. PubMed ID: 24526372
[TBL] [Abstract][Full Text] [Related]
9. Preventive effects of raloxifene and melatonin in N-methyl-N-nitrosourea-induced mammary carcinogenesis in female rats.
Kubatka P; Bojková B; Kalická K; Chamilová M; Adámeková E; Ahlers I; Ahlersová E; Cermáková M
Neoplasma; 2001; 48(4):313-9. PubMed ID: 11712685
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of selective estrogen receptor modulators in nude mice bearing human transitional cell carcinoma.
Sonpavde G; Okuno N; Weiss H; Yu J; Shen SS; Younes M; Jian W; Lerner SP; Smith CL
Urology; 2007 Jun; 69(6):1221-6. PubMed ID: 17572228
[TBL] [Abstract][Full Text] [Related]
11. Endometrial safety: a key hurdle for selective estrogen receptor modulators in development.
Pinkerton JV; Goldstein SR
Menopause; 2010; 17(3):642-53. PubMed ID: 20107426
[TBL] [Abstract][Full Text] [Related]
12. The role of selective estrogen receptor modulators on breast cancer: from tamoxifen to raloxifene.
Lee WL; Cheng MH; Chao HT; Wang PH
Taiwan J Obstet Gynecol; 2008 Mar; 47(1):24-31. PubMed ID: 18400579
[TBL] [Abstract][Full Text] [Related]
13. Comparative study of the short-term effects of a novel selective estrogen receptor modulator, ospemifene, and raloxifene and tamoxifen on rat uterus.
Zheng H; Kangas L; Härkönen PL
J Steroid Biochem Mol Biol; 2004 Feb; 88(2):143-56. PubMed ID: 15084346
[TBL] [Abstract][Full Text] [Related]
14. TAS-108, a novel oral steroidal antiestrogenic agent, is a pure antagonist on estrogen receptor alpha and a partial agonist on estrogen receptor beta with low uterotrophic effect.
Yamamoto Y; Shibata J; Yonekura K; Sato K; Hashimoto A; Aoyagi Y; Wierzba K; Yano S; Asao T; Buzdar AU; Terada T
Clin Cancer Res; 2005 Jan; 11(1):315-22. PubMed ID: 15671561
[TBL] [Abstract][Full Text] [Related]
15. Effects of the selective estrogen receptor modulator ospemifene on bone in rats.
Kangas L; Härkönen P; Väänänen K; Peng Z
Horm Metab Res; 2014 Jan; 46(1):27-35. PubMed ID: 24108389
[TBL] [Abstract][Full Text] [Related]
16. Ospemifene and 4-hydroxyospemifene effectively prevent and treat breast cancer in the MTag.Tg transgenic mouse model.
Burich RA; Mehta NR; Wurz GT; McCall JL; Greenberg BE; Bell KE; Griffey SM; DeGregorio MW
Menopause; 2012 Jan; 19(1):96-103. PubMed ID: 21926925
[TBL] [Abstract][Full Text] [Related]
17. Chemoprevention with antiestrogens: the beginning of the end for breast cancer. Daniel G. Miller Lecture.
Jordan VC
Ann N Y Acad Sci; 2001 Dec; 952():60-72. PubMed ID: 11795444
[TBL] [Abstract][Full Text] [Related]
18. Differential effects of selective oestrogen receptor modulators (SERMs) tamoxifen, ospemifene and raloxifene on human osteoclasts in vitro.
Michael H; Härkönen PL; Kangas L; Väänänen HK; Hentunen TA
Br J Pharmacol; 2007 Jun; 151(3):384-95. PubMed ID: 17420779
[TBL] [Abstract][Full Text] [Related]
19. Effects of a new clinically relevant antiestrogen (GW5638) related to tamoxifen on breast and endometrial cancer growth in vivo.
Dardes RC; O'Regan RM; Gajdos C; Robinson SP; Bentrem D; De Los Reyes A; Jordan VC
Clin Cancer Res; 2002 Jun; 8(6):1995-2001. PubMed ID: 12060645
[TBL] [Abstract][Full Text] [Related]
20. Use of SERMs for treatment in postmenopausal women.
Pinkerton JV; Thomas S
J Steroid Biochem Mol Biol; 2014 Jul; 142():142-54. PubMed ID: 24373794
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
